A

Atossa Therapeutics

D
ATOS
USD
0.01
(0.6711%)
Market Closed
14,282.00
Volume
-0.23
EPS
-
Div Yield
-7.142857
P/E
188,636,124.00
Market Cap
Today
0.6711%
1 Week
6.383%
1 Month
6.383%
6 Months
-10.714%
12 Months
114.102%
Year To Date
70.358%
All Time
-99.492%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SRNE
(%)
USD
T
TNXP
0.0006
(0.4277%)
USD
I
INO
0.02
(0.3617%)
USD
A
ARCT
0.85
(4.5285%)
USD
V
VXRT
-0.0417
(-5.7621%)
USD
C
CODX
-0.035
(-2.9787%)
USD
B
BNGO
-0.0149
(-5.068%)
USD
I
IDT
0.36
(0.7201%)
USD

Title:
Atossa Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Do you need help or have a question?
Contact Us